PARSIPPANY, NJ, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) today announced
that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference
at the W Hotel, Fort Lauderdale, Florida - on Tuesday, January 29th at 1:30 pm Eastern Standard Time in Studio 1.
A high-definition, video webcast of the presentation will be available the following day on the Company's
website (www.interpacediagnostics.com), and as part of a complete catalog of presentations available at
Noble Capital Markets’ Conference website: www.nobleconference.com and on the new investor portal created by Noble called Channelchek:
www.channelchek.com. The webcast will be archived on the company's website, the NobleCon website
and on Channelchek.com for 90 days following the event.
About Interpace Diagnostics Group, Inc.
Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a
clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts;
ThyGeNEXT™ for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the
diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates
lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being “soft launched” with
key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as
important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US
and over time can progress to esophageal cancer. The Company’s data base includes data from over 50,000 patients who have been
tested using the Company’s current products, including over 25,000 molecular tests for thyroid nodules. Interpace has been
designated by the 2018 edition of CIO Applications as one of the top 10 companies for providing bioinformatics solutions.
Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care
based on rigorous science. For more information, please visit Interpace’s website at www.interpacediagnostics.com.
About Noble Capital Markets, Inc.
2019 marks Noble Capital Markets’ 35th anniversary. The Company is an equity-research driven, full-service,
investment & merchant banking boutique focused on emerging growth companies. In addition to NobleCon, Noble hosts numerous
“non-deal” corporate road shows across the United States and Canada. In late 2018, Noble launched Channelchek.com which features
advanced market data, institutional-quality research, balanced news, videos and podcasts covering more than 6,000 emerging growth
companies. There is no cost for investors to join. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating
to the Company's future financial and operating performance, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements
also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially
different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other
factors include, but are not limited to, the Company’s history of losses, the Company's ability to adequately finance the business,
the market's acceptance of its molecular diagnostic tests, its ability to retain or secure reimbursement, its ability to secure
additional business and generate higher profit margins through sales of its molecular diagnostic tests, in-licensing or other
means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and its ability
to maintain its NASDAQ listing. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time
to time in the Company's SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed
on March 23, 2018, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and
assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as
of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update
publicly any forward-looking statements for any reason.
CONTACTS:
Interpace Diagnostics
Investor Relations
Joseph Green / Wiktoria O’Hare
646-653-7030 / 7028
jgreen@edisongroup.com/ wohare@edisongroup.com
